Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus TEXACORT.
DEXAMETHASONE INTENSOL vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of gene transcription.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
0.75-9 mg/day orally in divided doses every 6-12 hours; for anti-inflammatory/immunosuppressive effects, initial dose 0.75-9 mg/day; for cerebral edema, 10 mg IV then 4 mg IM/IV every 6 hours.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours (adults); clinically, biological half-life (duration of HPA axis suppression) is longer (24-72 hours).
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal (approximately 65-80% as metabolites, <10% as unchanged drug); biliary/fecal (minor).
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category D/X
Category C
Corticosteroid
Corticosteroid